

**AMENDMENTS TO THE CLAIMS WITH MARKINGS TO SHOW CHANGES
MADE, AND LISTING OF ALL CLAIMS WITH PROPER IDENTIFIERS**

Claims 1-23 are cancelled

24. (Currently amended) A vaccine for vaccinating a living being against infections by leishmania, the said vaccine comprising:

 a DNA expression construct comprising covalently-closed, linear deoxyribonucleotide molecules;

 said deoxyribonucleotide molecules each comprising a linear double-stranded region;

 said double-stranded region comprising single strands being linked by short, single-stranded loops of deoxyribonucleic acid nucleotides;

 said double strand-forming single strands comprising:

 a terminator sequence, and

 a coding sequence encoding at least the p36 LACK antigen under control of a promoter sequence and operable in the living being to be immunized;

 said DNA expression construct being covalently linked to at least one oligopeptide to increase transfection efficacy;

 said at least one oligopeptide comprises 3 to 30 amino acids; at least half of said amino acids of said at least one oligopeptide are members of a group comprising arginine and lysine; wherein the vaccine further comprises at least one oligopeptide consisting of the amino acid sequence of SEQ ID 3.